DOCSLIB.ORG

Drug Pipeline MONTHLY UPDATE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Pipeline MONTHLY UPDATE Drug Pipeline MONTHLY UPDATE Critical updates in an ever changing environment March 2020 NEW DRUG INFORMATION ™ ● Anjeso (meloxicam IV): The U.S. Food and Drug Administration (FDA) approved Baudax Bio’s Anjeso for the treatment of moderate-to-severe pain. Anjeso has 30mg of meloxicam per mL and is health care administered as a once-daily intravenous bolus injection. Anjeso was approved based on two Phase 3 trials that evaluated postoperative pain in patients compared to placebo. Results demonstrated statistically significant reduction in the pain, based on the numeric pain rating scale (NPRS: baseline of 6.8) as the primary end point over the first 48 hours.1 Approval came after two complete response letter (CRL) denials from the FDA concerning onset and duration of the medication. Baudax Bio plans on launching Anjeso in late April or early May 2020 with a cost of $94 per treatment.2 ™ ● Twirla (ethinyl estradiol and levonorgestrel transdermal system): Agile Therapeutics’ Twirla received an FDA approval as a low dose contraceptive patch for the prevention of pregnancy. Twirla is a once weekly patch that Agile Therapeutics states should help increase patient compliance. As part of Twila’s approval, the FDA is requiring Agile Therapeutics to conduct a long-term prospective study comparing the risks for venous thromboembolism (VTE) and arterial thromboembolism (ATE) in new users of Twirla versus other combined hormonal contraceptives. The final study report for the Twirla study is scheduled to be submitted to the FDA in November 2032, with interim safety data reporting in November 2026. The FDA has requested additional post-marketing commitment from Agile Therapeutics to assess the residual drug content and strength.3 Currently, the only other transdermal patch available on the market is the generic version of Ortho Evra, Xulane®, that delivers 150mcg of a different progestin, norelgestromin, and 35mcg of ethinyl estradiol per day.4 Twirla is set to launch in fourth quarter 2020 with pricing to follow.5 ™ ● Vyepti (eptinezumab-jjmr): The FDA approved Adler BioPharmaceuticals’ Vyepti for the prevention of migraine. Vyepti is the first intravenous calcitonin gene-related peptide (CGRP) (compared to available subcutaneous CGRPs) that is used as preventive migraine treatment, which should be administered once every three months. Vyepti’s approval is based off two clinical trials, PROMISE-1 and PROMISE-2, which measured the frequency of migraines patients had compared to baseline. The clinical trials demonstrated a treatment benefit over placebo that was observed for both doses (100mg, 300mg) of Vyepti. PROMISE-1 demonstrated that Vyepti decreased migraine days by three to four days per month compared to baseline. PROMISE-2 demonstrated Vyetpti reduced migraine days by seven to eight days per month compared to baseline.6 Adler BioPharmaceuticals plans to launch Vyepti in April 2020 with wholesale acquisition cost (WAC) of $5,980 per year.7 While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner. Drug Pipeline Monthly Update: March 2020 Page 2 ™ ● Nexletol (bempedoic acid): Esperion Therapeutics’ Nexletol has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Nexletol is a first-in-class ATP citrate lyase inhibitor. In the past few years, there has been excitement over PCSK9 monoclonal antibodies for the treatment of cholesterol, however these agents are delivered subcutaneously and are very expensive. The FDA-approved Nexletol, based on Phase 3 study, demonstrated an average of 18% reduction of LDL-C when used with moderate or high intensity statins, compared with placebo.8 Esperion Therapeutics plan to launch Nexletol on March 30, 2020 with a wholesale acquisition cost (WAC) of $10 per day.9 ™ ● Nexlizet (bempedoic acid and ezetimibe): Esperion Therapeutics’ Nexlizet has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Nexlizet was approved based on the Phase 3 Fixed Combination Drug Product lowering program, as well as safety data from the bempedoic acid tablet Phase 3 trial. Nexlizet lowered LDL-C by a mean of 38% compared to placebo when added on to maximally tolerated statins.10 Esperion Therapeutics plan to launch Nexlizet in July 2020 with a WAC of $10 per day. ™ ● Barhemsys (amisulpride): The FDA has approved Acacia Pharma’s Barhemsys for post-operative nausea and vomiting who are symptomatic despite having received prophylactic treatment. Barhemsys is an intravenous selective dopamine antagonist that can be used as prophylaxis or treatment as a single agent or in combination. The FDA approved Barhemsys based on four Phase 3 studies of more than 3,300 people. The studies demonstrated Barhemsys 10mg dose alone was significantly more effective at reducing post-operative nausea and vomiting compared to placebo (42% vs. 29%) and Barhemsys 5mg dose in combination with another antiemetic significantly reduced nausea and vomiting compared to placebo (58% vs 47%).11 Acacia Pharma plans to launch Barhemsys in the second half of 2020 with pricing to follow. ™ ● Nurtec ODT (rimegepant): Biohaven’s Nurtec orally disintegrating tablet (ODT) was approved by the FDA for treatment of acute migraine. Nurtec ODT is not for preventive migraine. Nurtec ODT is the only fast-dissolving formulation of the calcitonin gene-related peptide (CGRP) receptor antagonist class. Nurtec ODT, 75mg, can be taken without water and delivers pain relief within one hour, with sustained efficacy up to 48 hours.12 The FDA approved Nurtec ODT based on two Phase 3 clinical trials that demonstrated freedom from most bothersome symptoms at two hours post dose compared to placebo. Eighty-six percent of patients treated with Nurtec ODT did not require rescue medications within 24 hours post dose. In January 2020 the Institute for Clinical and Economic Review (ICER) evaluated CGRP receptor antagonist class and found Eli Lilly’s Reyvow® (lasmiditan), Biohaven’s Nurtec® (rimegepant) and Allergan’s Ubrelvy® (ubrogepant) all perform better than placebo, but evidence is not adequate to distinguish among them. For acute migraines, ICER states generic triptans would be the most effective and cost effective.13 Biohaven launched Nurtec ODT in March 2020, available in blister packs of eight tablets, with a WAC of $4,200-$4,600 annually.14 Drug Pipeline Monthly Update: March 2020 Page 3 ™ ● Durysta (bimatoprost sustained release implant): Allergan’s Durysta has been approved by the FDA for reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Durysta is a biodegradable intracameral implant that is limited to a single implant per eye and should not be re-administered to an eye previously treated with Durysta due to possible corneal endothelial cell loss. The FDA approved Durysta based on two Phase 3 studies of Durysta verses twice daily topical timolol 0.5% drops. Durysta reduced IOP by approximately 30% from baseline over the 12-week primary efficacy period (approximately 5-8mmHg in patients with a mean baseline IOP of 24.5mmHg) compared to competitior.15 Bimatoprost is available generically as an ophthalmic solution for the same indication as Allergan’s Durysta™ (bimatoprost sustained release implant). Launch and pricing pending. GENERIC DRUG INFORMATION ® ● Camptosar inj (irinotecan inj)+: Areva Pharmaceuticals has launched its generic version of Pfizer’s Camptosar injection for treatment of colorectal cancer. There are no longer any regulatory exclusivities. Camptosar generated $10 million in U.S. annual sales in 2018. ® ● Metastron inj (strontium-89 chloride inj)+: Biomed has launched its generic version of GE Health Care’s Metastron injection for treatment of bone pain in patients with skeletal metastases. Annual sales for Metastron are unknown. ® ● Phenobarbital inj (phenobarbital inj): Cameron Pharmaceuticals launched its version of Hikma’s Phenobarbital injection used as an anticonvulsant. Phenobarbital injection annual sales are unknown. ® ● Vimovo (naproxen/esomeprazole DR): Dr Reddy’s launched its version of Horizon Therapeutics’ Vimovo for treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Multiple manufacturers are set to launch in 2020. Vimovo generated $578 million in U.S. annual sales in 2018. ® ● Dymista (azelastine/fluticasone nasal spray): Apotex launched its version of Mylan’s Dymista for treatment of seasonal allergic rhinitis. Apotex is eligible for 180-day exclusivity. Multiple manufacturers are set to launch their generic versions of Dymista in August 2020. Dymista generated $141 million in U.S. annual sales in 2018. ® ● Geodon (ziprasidone inj): Gland Pharma launched its version of Pfizer’s Geodon injection for the treatment of schizophrenia. There are no longer any regulatory exclusivities on Geodon. Geodon injection generated
Load more

Recommended publications
  • Investigating the Inhibition Mechanism of L,D-Transpeptidase 5 from Mycobacterium Tuberculosis Using Computational Methods
    INVESTIGATING THE INHIBITION MECHANISM OF L,D-TRANSPEPTIDASE 5 FROM MYCOBACTERIUM TUBERCULOSIS USING COMPUTATIONAL METHODS BY: GIDEON FEMI TOLUFASHE 216076453 Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Pharmaceutical Chemistry School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 2018 PREFACE The work described in this thesis was conducted at the Catalysis and Peptide Research Unit, Westville Campus, University of KwaZulu-Natal, Durban, South Africa, under the supervision of Dr Bahareh Honarparvar, Prof. H.G. Kruger and Dr G.E.M. Maguire. This work has not been submitted in any form for any degree or diploma to any institution, where use has been made of the work of others, it is duly acknowledged in the text. Supervisors: Dr B. Honarparvar Date 30/10/2018 Prof. H. G. Kruger________________ Date ___________ Dr. G.E.M Maguire_______________ Date ___________ As candidate’s supervisor I agree to the submission of this thesis. i DECLARATION DECLARATION I- PLAGIARISM I, Gideon Femi Tolufashe declare that (i). The research reports in this thesis, except where otherwise indicated, is my original work. (ii). This thesis has not been submitted for any degree or examination at any other university. (iii). This thesis does not contain other person’s data, pictures, graphs or other information, unless specifically acknowledged as being sourced from other persons. (iv). This thesis does not contain other person’s writing, unless specifically acknowledged as being sourced from other researchers. Where other written sources have been quoted, then: a. Their words have been re-written, but the general information attributed to them has been referenced.
    [Show full text]
  • Tufts Health Unify 202 0 List of Covered Drugs (Formulary)
    Tufts Health Unify 202 0 List of Covered Drugs (Formulary) Effective: 12/01/2020 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855.393.3154 Seven days a week, from 8 a.m. to 8 p.m. TuftsHealthUnify.org Formulary ID: 20533 Version: 20 H7419_6507B Approved DISCRIMINATION IS AGAINST THE LAW Tufts Health Plan complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Tufts Health Plan does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. Tufts Health Plan: . Provides free aids and services to people with disabilities to communicate effectively with us, such as: — Written information in other formats (large print, audio, accessible electronic formats, other formats) . Provides free language services to people whose primary language is not English, such as: — Qualified interpreters — Information written in other languages If you need these services, contact Tufts Health Plan Member Services at 855.393.3154. If you believe that Tufts Health Plan has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Tufts Health Plan Attention: Civil Rights Coordinator, Legal Dept. 705 Mount Auburn St. Watertown, MA 02472 Phone: 888.880.8699 ext. 48000, [TTY number— 711 or 800.439.2370] Fax: 617.972.9048 Email: [email protected] You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Tufts Health Plan Civil Rights Coordinator is available to help you.
    [Show full text]
  • Suomen Lääketilasto 2019
    SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS ON MEDICINES FSM 2019 Keskeisiä lukuja lääkkeiden myynnistä ja lääkekorvauksista vuonna 2019 Milj. € Muutos vuodesta 2018, % Lääkkeiden kokonaismyynti 3 460 5,2 avohoidon reseptilääkkeiden myynti (verollisin vähittäismyyntihinnoin) 2 284 4,4 avohoidon itsehoitolääkkeiden myynti (verollisin vähittäismyyntihinnoin) 357 0,8 sairaalamyynti (tukkuohjehinnoin) 818 9,9 Lääkkeistä maksetut korvaukset 1 551 6,2 peruskorvaukset 316 3,0 erityiskorvaukset 1 029 5,2 lisäkorvaukset 205 17,7 Key figures for medicine sales and their reimburssement in 2019 € million Change from 2018, % Total sales of pharmaceuticals 3,460 5.2 prescription medicines in outpatient care (at pharmacy prices with VAT) 2,284 4.4 OTC medicines in outpatient care (at pharmacy prices with VAT) 357 0.8 sales to hospitals (at wholesale prices) 818 9.9 Reimbursement of medicine costs 1,551 6.2 Basic Refunds 316 3.0 Special Refunds 1,029 5.2 Additional Refunds 205 17.7 Lähde: Fimean lääkemyyntirekisteri, Kelan sairausvakuutuskorvausten tilastointitiedosto. Source: Finnish Medicines Agency, Drug Sales Register; Register of Statistical Information on National Health Insurance General Benefit Payments. SUOMEN LÄÄKETILASTO FINNISH STATISTICS ON MEDICINES 2019 Lääkealan turvallisuus- ja kehittämiskeskus Fimea ja Kansaneläkelaitos Finnish Medicines Agency Fimea and Social Insurance Institution Helsinki 2020 LÄÄKEALAN TURVALLISUUS- KANSANELÄKELAITOS JA KEHITTÄMISKESKUS FIMEA FINNISH MEDICINES AGENCY FIMEA SOCIAL INSURANCE INSTITUTION Lääketurvallisuus Analytiikka- ja tilastoryhmä Pharmacovigilance Section for Analytics and Statistics Mannerheimintie 166 Nordenskiöldinkatu 12 P.O. Box 55 P.O. Box 450 FI-00034 Fimea FI-00056 Kela Finland Finland [email protected] [email protected] Puh. 029 522 3341 Puh. 020 634 11 Tel. +358 29 522 3341 Tel.
    [Show full text]
  • Patch Development with New Drugs Versus Generic Development – Principles and Methods
    Patch development with new drugs versus generic development – principles and methods Dr. Barbara Schug SocraTec R&D, Oberursel , Germany www.socratec-pharma.de AGAH Workshop, The new European modified Release Guideline- from cook book to interpretation, Bonn, June 15th –16th, 2015 Some basics Physico-chemical properties / conventional patches small molecule < 500kDa lipophilic potent therapeutic concept which requires low fluctuation Skin controls release rate drug substance dispersed in adhesive matrix Patch controls release rate rate controlling membrane between drug reservoir and skin Currently marketed patches Year Generic (Brand) Names Indication 1979 Scopolamine (Transderm Scop®) Motion sickness 1982 Nitroglycerine (Nitroderm TTS) Angina pectoris 1984 Clonidine (Catapress TTS®) Hypertension 1986 Estradiol (Estraderm®) Menopausal symptoms 1990 Fentanyl (Duragesic®) Chronic pain 1991 Nicotine (Nicoderm®, Habitrol®, Prostep®) Smoking cessation 1993 Testosterone (Androderm®) Testosterone deficiency 1995 Lidocaine/epinephrine (Iontocaine®) Local dermal analgesia 1998 Estradiol/norethindrone (Combipatch®) Menopausal symptoms 1999 Lidocaine (Lidoderm®) Post-herpetic neuralgia pain 2001 Ethinyl estradiol/norelgestromin (OrthoEvra®) Contraception 2003 Estradiol/levonorgestrel (Climara Pro®) Menopause 2003 Oxybutynin (Oxytrol®) Overactive bladder 2004 Lidocaine/ultrasound (SonoPrep®) Local dermal anesthesia Source: modified from Wilson EJ, Three Generations: The Past, Present, and Future of Transdermal Drug Delivery Systems, May 2014
    [Show full text]
  • Joel L. Young, M.D
    Joel L. Young, M.D. 441 South Livernois Road, Suite 100 Rochester Hills, Michigan 48307 Phone: 248-608-8800 / Fax: 248-608-2490 / E-mail: [email protected] Professional History 2000 – Present: Chief Medical Officer and Founder, Clinical Trials Group at the Rochester Center for Behavioral Medicine, Rochester Hills, MI 1993 – Present: Medical Director and Founder, Rochester Center for Behavioral Medicine, Rochester Hills, MI (www.rcbm.net). 2008 (Current): Clinical Associate Professor of Psychiatry, Wayne State University, Detroit, MI. 2000 – 2007: Medical Director, Crittenton Network for Behavioral Health, Rochester, MI. 2000 – 2002: Chief of Staff, Department of Psychiatry, Crittenton Hospital, Rochester, MI. July, 1993 – 1997: Medical Director, Psychiatric Emergency Services, Crittenton Hospital. July, 1992 – June, 1993: Chief Resident of Adult Services, Department of Psychiatry, University of Michigan Hospitals, Ann Arbor, MI. Oct. 1991-Sept. 1993: Unit Psychiatrist, Bon Secours Adolescent Mental Health Unit, Grosse Pointe, MI. August, 1991 – 1996: Consulting Psychiatrist, Beacon Hill Clinic, Birmingham, MI. July, 1991 – June, 1992: Consulting Psychiatrist, Washtenaw County Community Mental Health Services, Ann Arbor, MI. July, 1990 – June, 1992: House Officer, Department of Psychiatry, University of Michigan Hospitals. June, 1989 – June, 1990: Intern, Departments of Internal Medicine, Pediatrics and Psychiatry, University of Michigan Hospitals. Boards 2018 Fellow: American Board of Psychiatry and Neurology 2017 Re-certification of Geriatric Qualifications by the American Board of Psychiatry and Neurology through 2027. 2017 Re-certification of Forensic Qualifications by the American Board of Psychiatry and Neurology through 2027 2014 Re-Certification by the American Board of Psychiatry and Neurology 2007 Re-certification by the American Board of Adolescent Psychiatry.
    [Show full text]
  • Supported by an Educational Grant from Sunovion Pharmaceuticals Inc. Faculty
    Supported by an educational grant from Sunovion Pharmaceuticals Inc. Faculty Leslie Citrome, MD, MPH C. Brendan Montano, MD Clinical Professor of Psychiatry and CT Clinical Research Behavioral Sciences Director, Principal Investigator New York Medical College Private Practice, Internal Medicine Valhalla, New York Cromwell, Connecticut Faculty Disclosure • Dr. Citrome: Consultant—Acadia, Alkermes, Allergan, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda; Royalties—Springer Healthcare (book), UpToDate (reviewer), Wiley (Editor in Chief, International Journal of Clinical Practice); Shareholder (and spouse)—Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer; Speaker—Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva. • Dr. Montano: Consultant—Allergan, Shire/Takeda Pharmaceutical Company Ltd., Sunovion Pharmaceuticals Inc., Arbor Pharmaceuticals Ltd.; Research Support—Allergan, Avanir, Sunovion Pharmaceuticals Inc., Tonix, BioHaven, Axsome Therapeutics, Arbor Pharmaceuticals Ltd.; Speakers Bureau— Allergan, Shire/Takeda Pharmaceutical Company Ltd., Arbor Pharmaceutical Ltd. Disclosure • The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). – The off-label and investigational use of antidepressants, topiramate,
    [Show full text]
  • F.8 Ethinylestradiol-Etonogestrel.Pdf
    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • Wellness Benefits
    Wellness Benefits University of South Alabama This schedule outlines services and items that the University of South Alabama considers a preventive service under this plan. These services must be performed by a physician in the University of South Alabama Health System provider network or by a dermatologist, endocrinologist, durable medical equipment provider, ancillary service provider, urologist, or rheumatologist provider (as applicable) in the entire VIVA HEALTH network. Many of these services are provided as part of an annual physical. This list does not apply to all VIVA HEALTH plans. Please refer to your Summary Plan Description to determine the terms of your health plan. PREVENTIVE SERVICE FREQUENCY/LIMITATIONS Well Baby Visits (Age 0-2) As recommended per guidelines1 Routine screenings, tests, and immunizations As recommended per guidelines Well Child Visits (Age 3-17) One per year at PCP2 Routine screenings, tests, & immunizations As recommended per guidelines HIV screening and counseling As recommended per guidelines Obesity screening As recommended per guidelines Hepatitis B virus screening As recommended per guidelines Sexually transmitted infection counseling Annually Skin cancer behavioral counseling (Beginning at age 10) As recommended per guidelines Routine Physical (Age 18+) One per year at PCP2 Alcohol misuse screening and counseling Annually Blood pressure screening Annually Cholesterol screening As recommended per guidelines Depression screening Annually Diabetes screening As recommended per
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Ferric Maltol) Capsules, for Oral Use ------ADVERSE REACTIONS------Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------WARNINGS AND PRECAUTIONS----------------------- These highlights do not include all the information needed to use • IBD flare: Avoid use in patients with IBD flare (5.1) ACCRUFERTM safely and effectively. See full prescribing • Iron overload: Accidental overdose of iron products is a leading information for ACCRUFER. cause of fatal poisoning in children under 6. Keep out of reach of children. (5.2) ACCRUFER (ferric maltol) capsules, for oral use --------------------------- ADVERSE REACTIONS------------------------------ Initial U.S. Approval: 2019 Most common adverse reactions (incidence > 1%) are flatulence, diarrhea, constipation, feces discolored, abdominal pain, nausea, -----------------------------INDICATIONS AND USAGE-------------------------- vomiting and abdominal discomfort/distension. (6.1) ACCRUFER is an iron replacement product indicated for the treatment of iron deficiency in adults. (1) To report SUSPECTED ADVERSE REACTIONS, contact [name of manufacturer] at [toll-free phone #] or FDA at 1-800-FDA-1088 or ------------------------DOSAGE AND ADMINISTRATION---------------------- www.fda.gov/medwatch. • 30 mg twice daily on an empty stomach (2.1) • Continue as long as necessary to replenish body iron stores (2.1) ------------------------------DRUG INTERACTIONS------------------------------- • Dimercaprol: Avoid concomitant use. (7.2) ---------------------DOSAGE FORMS AND STRENGTHS---------------------- • Oral Medications: Separate administration of ACCRUFER from Capsules:
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]